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Abstract 
Background: An important portion of asthmatics do not respond to current therapies. Thus, the need for new 
therapeutic drugs is urgent. We have demonstrated a critical role for PARP in experimental asthma. Olaparib, a PARP 
inhibitor, was recently introduced in clinical trials against cancer. The objective of the present study was to examine 
the efficacy of olaparib in blocking established allergic airway inflammation and hyperresponsiveness similar to those 
observed in human asthma in animal models of the disease.
Methods: We used ovalbumin (OVA)‑based mouse models of asthma and primary CD4+ T cells. C57BL/6J WT or 
PARP‑1−/− mice were subjected to OVA sensitization followed by a single or multiple challenges to aerosolized OVA or 
left unchallenged. WT mice were administered, i.p., 1 mg/kg, 5 or 10 mg/kg of olaparib or saline 30 min after each OVA 
challenge.
Results: Administration of olaparib in mice 30 min post‑challenge promoted a robust reduction in airway eosino‑
philia, mucus production and hyperresponsiveness even after repeated challenges with ovalbumin. The protective 
effects of olaparib were linked to a suppression of Th2 cytokines eotaxin, IL‑4, IL‑5, IL‑6, IL‑13, and M‑CSF, and ovalbu‑
min‑specific IgE with an increase in the Th1 cytokine IFN‑γ. These traits were associated with a decrease in splenic 
CD4+ T cells and concomitant increase in T‑regulatory cells. The aforementioned traits conferred by olaparib adminis‑
tration were consistent with those observed in OVA‑challenged PARP‑1−/− mice. Adoptive transfer of Th2‑skewed OT‑
II‑WT CD4+ T cells reversed the Th2 cytokines IL‑4, IL‑5, and IL‑10, the chemokine GM‑CSF, the Th1 cytokines IL‑2 and 
IFN‑γ, and ovalbumin‑specific IgE production in ovalbumin‑challenged PARP‑1−/−mice suggesting a role for PARP‑1 
in CD4+ T but not B cells. In ex vivo studies, PARP inhibition by olaparib or PARP‑1 gene knockout markedly reduced 
CD3/CD28‑stimulated gata‑3 and il4 expression in Th2‑skewed CD4+ T cells while causing a moderate elevation in 
t‑bet and ifn‑γ expression in Th1‑skewed CD4+ T cells.
Conclusions: Our findings show the potential of PARP inhibition as a viable therapeutic strategy and olaparib as a 
likely candidate to be tested in human asthma clinical trials.
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Background
Contrary to a number of chronic diseases, asthma inci-
dence is on the rise [1]. In the United States alone, more 
than 20 million individuals suffer from the disease. A siz-
able portion of these asthmatics do not respond to the 
existing drugs [2]. Accordingly, the need for new drugs as 
mono or adjuvant therapies is immediate.
The pathogenesis of asthma involves several cellular 
and non-cellular factors including Th2 and Th17 CD4+ 
T cells as well as B cells in addition to circulating factors 
such as IL-4, IL-5, IL-13 and many others [3]. Targeting 
the function of these cells and the ensuing production 
of Th2 cytokines and IgE has been a critical objective 
both in the clinic and in the laboratory. Our laboratory 
pioneered the studies demonstrating the involvement of 
poly(ADP-ribose)polymerase (PARP)-1 in asthma [4–8]. 
Our studies as well as those of others [9–13] suggest that 
the protein may constitute a viable target for the treat-
ment of the disease. PARP-1, a member of a large fam-
ily of proteins, is a DNA repair-associated enzyme that 
participates in the recruitment and trafficking processes 
of DNA repair proteins and histones to the DNA lesions 
primarily through base excision repair [14]. However, 
our laboratory and many others have suggested a role for 
the enzyme in a number of inflammatory conditions and 
regulation of transcription. We have shown that it con-
trols NF-κB nuclear trafficking and thus transcription 
of NF-κB-dependent genes including those critical for 
asthma manifestation [15–17]. We have also shown that 
PARP-1 controls the fate of STAT-6 upon IL-4 or allergen 
exposure both in vitro and in an animal model of the dis-
ease through a calpain-dependent mechanism [8].
An ultimate goal of our studies is to explore the pos-
sibility that PARP can be targeted for therapy to treat 
asthma in human subjects. A great deal of effort has been 
made to generate potent inhibitors of the enzyme tar-
geting cancer and inflammatory diseases [18]. Recently, 
olaparib (AZD2281), a small molecule inhibitor of 
PARP-1 and PARP-2 showed great potential for the treat-
ment of BRCA-negative breast and ovarian cancer [19]. 
These neoplastic conditions were specifically targeted 
because the cancer cells accumulate fatal dsDNA breaks 
when exposed to DNA damaging agents in the absence 
of PARP activity leading a synthetic lethality phenotype 
[20]. Because this process occurs only in BRCA-mutant 
cancer cells, PARP inhibition is not expected to affect 
normal cells. In several clinical trials, the drug showed a 
remarkable therapeutic efficacy with an acceptable safety 
index in cancer patients [21]. It is noteworthy that other 
PARP inhibitors have also been developed and are cur-
rently tested in more than 20 clinical trials.
In the current study, we aimed to test the efficacy 
of olaparib in experimental asthma. We specifically 
examined whether olaparib administration at doses that 
can be translated to human therapy blocks some or all 
asthma-like traits. We also examined whether the drug 
blocks already established disease to mimic what actually 
occurs in human asthmatics.
Methods
Animals
C57Bl/6J wild type (WT) and OT-II mice (6–8  weeks 
old) were purchased from Jackson Laboratories (Bar Har-
bor, ME, USA). C57BL/6 PARP-1−/− mice were gener-
ated through a backcrossing with C57BL/6 WT mice for 
eleven generations. The last generation was interbred to 
generate the C57BL/6 PARP-1−/− mice. WT mice gen-
erated through the PARP-1+/− mice breeding were also 
included in the experiment. Mice were bred in a spe-
cific-pathogen free facility at LSUHSC, New Orleans, 
LA, and allowed unlimited access to sterilized chow and 
water. Maintenance, experimental protocols, and proce-
dures were approved by the LSUHSC Animal Care & Use 
Committee.
Ovalbumin (OVA) sensitization and challenge, Airway 
hyper responsiveness (AHR), organ recovery, staining, Th2 
cytokine and IgE assessments, and FACS analysis
Mice were sensitized to chicken OVA (Sigma-Aldrich, St. 
Louis, MO, USA) as described [6]. The mice were then 
challenged with aerosolized OVA for 30  min once (sin-
gle challenge) or once a day for 3  days (multiple chal-
lenge). Control groups were not sensitized or challenged. 
Additional groups of mice received i.p. 1, 5, or 10  mg/
kg olaparib (Selleckchem, Pittsburgh, PA, USA) in saline 
30  min after OVA challenge. AHR, organ recovery, his-
topathology, bronchoalveolar lavage (BAL), cytokine and 
OVA-specific IgE assessment, and FACS analysis were 
performed as described [6, 22, 23]. To determine CD4+ 
T cell populations, spleens were processed to gener-
ate single cell suspensions after which splenocytes were 
stained with antibodies to mouse CD3e (145-2c11-APC) 
and CD4-FITC (clone RM4-5) (both from e-Bioscience, 
San Diego, CA, USA). To determine T-regulatory (T-reg) 
cell populations, splenocytes were stained with CD4 
(GK1.5-FITC) and CD25-APC (clone PC61) (from Biole-
gend, San Diego, CA, USA), and intracellularly with anti-
mouse Foxp3 (FJK-16s)-PE (e-Bioscience) followed by 
FACS analysis. The multiplex assay and FACS were con-
ducted at the LSUHSC Comprehensive Alcohol Research 
Center Core.
CD4+ T cell purification, Th1/Th2 skewing, TCR stimulation, 
Adoptive transfer, and RT‑PCR
OT-II or WT mice were sacrificed and splenic CD4+ 
T cells were isolated by negative selection (Stem Cell 
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Technologies, Vancouver, Canada). Purified CD4+ T 
cells were stimulated on coated plates with antibodies to 
CD3 (1 μg/ml) and CD28 (0.5 μg/ml) (e-bioscience, San 
Diego, CA, USA) then skewed toward a Th1 or Th2 phe-
notype as described [23]. WT CD4+ T cells were skewed 
in the absence or presence of 5 μM olaparib. RNA was 
extracted using Qiagen RNA extraction kit according 
to the manufacturer instructions. The extracted total 
RNA was used for the generation of cDNA using reverse 
transcriptase III (Invitrogen) and quantitative PCR was 
conducted using primer sets (IDT, San Jose, CA, USA) 
specific for mouse gata-3, il-4, t-bet, ifn-γ, or β-actin as 
described [23, 24]. Quantitative determination of gene 
expression levels using a 2-step cycling protocol was con-
ducted on a MyIQ Cycler (Bio-Rad, Hercules, CA, USA). 
Relative expression levels were calculated using the 2[−
Delta Delta C(T)] method [25]. Quantities of all targets 
were normalized to the mouse β-actin gene.
Th2-like cells from OT-II mice were administered i.v. 
into the tail vein of recipient mice (1 × 106 cells/mouse). 
All mice were subjected to OVA challenge daily for 
4 days. Mice were sacrificed 48 h after the last challenge.
Data analysis
All data are expressed as means ± SEM of values from at 
least five mice per group unless stated otherwise. PRISM 
software (GraphPad, San Diego, CA, USA) was used to 
analyze the differences between experimental groups by 
one way analysis of variance (ANOVA) followed by Tuk-
ey’s multiple comparison test.
Results
Olaparib blocks airway eosinophilia, mucus and IgE 
production, and AHR upon a single or repeated challenge 
with OVA in a mouse model of asthma
Figure 1a shows that a single administration of olaparib 
at the 1  mg/kg dose almost completely prevented the 
elevation of OVA-specific IgE production in BAL flu-
ids (BALF) but not sera collected from OVA-sensitized 
and challenged mice. A slightly higher dose of 5  mg/
kg was sufficient to cause a significant reduction in the 
sera levels of OVA-specific IgE. As expected, PARP-1 
gene deletion provided similar protection. The blockade 
in IgE production coincided with a significant reduc-
tion in the total number of inflammatory cells recruited 
to the lung of treated animals with a prominent effect on 
eosinophils, neutrophils, and lymphocytes (Figure  1b). 
Figure  1c shows an example of the inflammatory cell 
infiltration into the lungs of OVA-challenged mouse and 
the effective protection against such infiltration by treat-
ment with 5 mg/kg olaparib as assessed by H&E staining. 
Treatment with olaparib also reduced mucus produc-
tion as assessed by Periodic acid–Schiff (PAS) staining 
(Figure 1d). Figure 1e shows that administration of 5 mg/
kg olaparib almost completely prevented AHR manifesta-
tion to increasing doses of methacholine. The effects of 
olaparib administration were similar to those observed in 
OVA-challenged PARP-1−/− mice.
The protective effect of olaparib against a single OVA 
challenge does not necessarily mean that the drug would 
maintain its anti-inflammatory efficacy upon multiple 
challenges. Accordingly, mice were challenged daily for 
three consecutive days and received increasing doses of 
olaparib 30  min after every challenge. Figure  2a shows 
that olaparib maintained a remarkable efficacy in reduc-
ing OVA-specific IgE production with a maximal protec-
tion conferred by the 5 mg/kg dose of the drug. At this 
dose, the drug exerted a pronounced protection against 
the inflammatory burden induced by repeated OVA chal-
lenges including eosinophilia (Figure 2b, c), mucus pro-
duction (Figure  2d), and AHR (Figure  2e) in a manner 
similar to that conferred by PARP-1 gene deletion.
Olaparib treatment differentially affects production of Th1 
and Th2 cytokines
Figure  3a shows that both single and multiple OVA 
challenge induced considerable levels of several Th2 
cytokines including eotaxin, IL-4, IL-5, IL-6, IL-13, and 
M-CSF, and that olaparib administration suppressed pro-
duction of these cytokines. It is important to note that 
in the single OVA challenge model, olaparib at 1 mg/kg 
provided a remarkable reduction in the production of the 
aforementioned cytokines most notably eotaxin, IL-4, 
and M-CSF. Upon repeated OVA challenges, the lowest 
dose of olaparib only reduced the levels of IL-5 and IL-6. 
However, the 5 mg/kg dose was sufficient to almost com-
pletely block the production of all measured cytokines. 
It is worth mentioning that the effect of PARP inhibition 
either pharmacologically or by gene knockout on IL-2 
production was marginal in both the single and repeated 
OVA challenge models (Figure 3b).
Figure 3c shows that the levels of IFN-γ were reduced 
upon a single or repeated challenge with OVA. Such 
decrease was prevented by administration of the PARP 
inhibitor. Interestingly, the levels of IFN-γ were markedly 
lower in control PARP-1−/− mice and, unlike in olaparib-
treated animals, OVA challenge did not cause an eleva-
tion of the cytokine in the knockout animals.
PARP inhibition by olaparib or gene knockout prevents 
OVA challenge‑induced elevation in CD4+ T cells 
but increases T‑reg cell population in spleen of treated 
mice
Given the substantial effect of PARP inhibition on Th2 
cytokine production, we next examined whether PARP 
inhibition achieved such effect by modulating CD4+ 
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Figure 1 C57BL/6J WT or PARP‑1−/− mice were subjected to OVA sensitization followed by a single challenge to aerosolized OVA or left unchal‑
lenged. WT mice were administered, i.p., 1 mg/kg, 5 mg/kg or 10 mg/kg of olaparib or saline thirty minutes after OVA challenge. Mice were 
sacrificed 48 h later and lungs were subjected to formalin fixation or BAL. a Assessment of BALF or sera collected from the different experimental 
groups 48 h after OVA challenge for OVA‑specific IgE using sandwich ELISA. b Cells of BALF were differentially stained, and total cells, eosinophils, 
macrophages, lymphocytes, and neutrophils were counted. Data are expressed as total number of cells per mouse. Data are means ± SD of values 
from at least six mice per group. c Lung sections from OVA‑challenged mice that were treated with either saline or olaparib were subjected to H&E 
or d PAS staining. e Mice were sensitized and challenged with OVA as described above. A group of WT mice received an injection of 5 mg/kg of 
olaparib. Penh was recorded 24 h later using a whole body plethysmograph system before and after the indicated concentrations of aerosolized 
methacholine (MeCh). Results are plotted as maximal fold increase of Penh relative to baseline and expressed as mean ± SEM where n = 6 mice per 
group. For a, b, and e asterisk difference from control unchallenged mice, p < 0.01; hash difference from OVA‑challenged mice; p < 0.01. For c and d 
bar 5 μm.
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Figure 2 WT or PARP‑1−/− mice were subjected to OVA sensitization followed by triple challenge (Multiple) or left unchallenged. WT mice were 
administered, i.p., 1 mg/kg, 5 mg/kg or 10 mg/kg of olaparib or saline thirty minutes after each challenge. Mice were sacrificed 48 h later and lungs 
were subjected to formalin fixation or BAL. a Assessment of BALF or sera collected from the different experimental groups 48 h after the last chal‑
lenge for OVA‑specific IgE. b Cells of BALF were differentially stained, and total cells, eosinophils, macrophages, lymphocytes, and neutrophils were 
counted. Data are means ± SD of values from at least six mice per group and are expressed as total number of cells per mouse. Lung sections from 
multiple OVA‑challenged mice that were treated with either saline or olaparib were subjected to H&E c or PAS d staining. e Mice were sensitized 
and challenged with OVA as described above. A group of WT mice received an injection of 5 mg/kg of olaparib. Penh was recorded 24 h later using 
a whole body plethysmograph system before and after the indicated concentrations of aerosolized methacholine (MeCh). Results are plotted as 
maximal fold increase of Penh relative to baseline and expressed as mean ± SEM where n = 6 mice per group. For a, b, and  e asterisk difference 
from control unchallenged mice, p < 0.01; hash difference from OVA‑challenged mice; p < 0.01. For c and d bar 5 μm.
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T cell populations in spleens of OVA-challenged mice. 
PARP inhibition by olaparib or gene knockout did not 
cause any noticeable change in the overall number of 
cells in spleens of control or OVA-challenged mice (data 
not shown). However, PARP inhibition prevented the 
increase in the percentage of CD4+ T cells both upon 
a single (Figure  4a) or repeated (Figure  4b) OVA chal-
lenge. Conversely, the percentage of T-reg cell population 
a
b c
Figure 3 WT or PARP‑1−/− mice were subjected to OVA sensitization followed by a single or triple challenge (Multiple) or left unchallenged. WT 
mice were administered i.p. 1 mg/kg, 5 or 10 mg/kg of olaparib or saline 30 min after each challenge. Mice were sacrificed 48 h later and lungs were 
subjected to BAL. Assessment of BALF from the different groups for Th2 cytokines eotaxin, IL‑4, IL‑5, IL‑6, IL‑13, or M‑CSF (a), IL‑2 (b) or INF‑γ (c). Data 
are means ± SD of values from at least six mice per group. Asterisk difference from control unchallenged mice, p < 0.01; hash difference from OVA‑
challenged mice; p < 0.01.
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increased upon olaparib administration. The T-reg cell 
population in naïve untreated PARP-1−/− mice was higher 
than that in OVA-challenged WT mice. However, single 
or repeated OVA challenge did not culminate in an addi-
tional increase of such population in the mutant mice. It is 
unclear whether PARP inhibition-associated elevation in 
T-reg cell population was due to changes in the number of 
CD4+ T cells. However, these results suggest a potentially 
important role for PARP-1 in CD4+ T cell function.
PARP inhibition by olaparib or gene knockout modulates 
CD4+ T cell function by differentially affecting expression 
of gata‑3 and t‑bet in CD3/CD28‑treated CD4+ T cells
We next examined whether the effect of olaparib on Th2 
and Th1 cytokines was by controlling mRNA expression 
of key transcription factors that regulate the expression of 
these cytokines focusing primarily on gata-3, t-bet, IL-4, 
and IFN-γ. To this end, CD4+ T cells were skewed toward a 
Th1 or Th2 phenotype and stimulated with anti-CD3/CD28 
antibodies in the presence or absence of 5 μM olaparib. Fig-
ure  5 shows that olaparib markedly reduced CD3/CD28-
stimulated GATA-3 mRNA expression with a concomitant 
reduction in IL-4 mRNA expression. Interestingly, olaparib 
treatment caused an elevation in T-bet and IFN-γ mRNA 
expression in Th1-skewed CD4+ T cells. These results are 
consistent with the effect of PARP inhibition on the Th1 and 
Th2 cytokines observed in the animal models.
Adoptive transfer of in vitro Th2‑skewed OT‑II CD4+ T 
cells is sufficient to reverse airway inflammatory cell 
recruitment, Th2 cytokine production, and OVA‑specific 
IgE secretion in OVA‑exposed PARP‑1−/− mice
Overall, the above results suggest that PARP-1 not only 
plays a role in CD4+ T cell recruitment but also plays a 
a
b
Figure 4 WT or PARP‑1−/− mice were subjected to OVA sensitization followed by a single or triple challenge (Multiple) or left unchallenged. WT 
mice were administered i.p. 5 mg/kg of olaparib or saline 30 min after each challenge or left untreated. All mice were sacrificed 48 h later. Spleens 
from the different experimental groups were used to generate single‑cell suspensions. a Cells were stained with antibodies to CD3e (145‑2c11‑APC) 
and CD4 (GK1.5‑PE). b A portion of the cells was also subjected to intracellular staining with antibodies to Foxp3 (FJK‑16s‑ PE) in addition to antibod‑
ies to CD4 (GK1.5‑FITC) and CD25 (PC61.5‑ APC). Stained cells were then analyzed by FACS. Asterisk difference from control WT mice, p < 0.01; hash 
difference from WT‑OVA challenged mice, p < 0.01.
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critical role in the function of these cells. To test the role 
of PARP-1 in CD4+ T cell function during an allergic 
response, we examined whether adoptive transfer of WT 
CD4+ T cells isolated from OT-II mice that were skewed 
in  vitro toward a Th2 phenotype reverses asthma-like 
traits in naïve PARP-1−/− mice upon OVA exposure. Fig-
ure 6a shows that, indeed, transfer of Th2-skewed CD4+ 
T cells was sufficient to reverse lung inflammation. Such 
effect occurred concomitantly with an elevation in OVA-
specific IgE production (Figure 6b) and production of the 
Th2 cytokines IL-4, IL-5, IL-10, and GM-CSF (Figure 6c) 
in addition to the Th1 cytokines IL-2 and IFN-γ (Fig-
ure 6d) in PARP-1−/− mice upon exposure to aerosolized 
OVA to levels equivalent or close to those observed in 
the WT counterparts. These results clearly suggest a crit-
ical role for PARP-1 in the CD4+ T cell function.
Discussion
In this study, we show that olaparib administration is 
highly efficient in blocking established AAI and AHR, 
which constitute two major components of asthma. We 
also provide evidence for an important role for PARP-1 
in CD4+ T cell function without a prominent effect on 
B cell function. Moreover, our results support the possi-
bility that PARP inhibition may also influence T-reg cell 
accumulation as an additional mechanism in dampen-
ing allergic response in our experimental models. Lastly, 
the effect of olaparib on CD4+ T cell function may be 
strongly linked to the ability of PARP-1 to control expres-
sion of the transcription factor GATA-3.
Olaparib treatment was very effective in blocking 
repeated challenges to OVA in mice. Remarkably, a dose 
as low as 1  mg/kg of the PARP inhibitor was sufficient 
to confer protection against the manifestation of several 
asthma-like traits including AHR. As very recently shown 
by one of us [26], olaparib is also effective in reducing 
lung inflammation induced by LPS and inhibits expres-
sion of several inflammatory factors including VCAM-1 
and TNF-α. Our results show that a major role of PARP 
may be in the function of CD4+ T cells. This is supported 
by the finding that an adoptive transfer of OT-II CD4+ 
T cells was sufficient to reverse lung cellularity and pro-
duction of Th2 cytokines and IgE to levels compara-
ble to those detected in similarly treated WT mice. The 
Th1 cytokines were also elevated. An increase in IL-2 is 
expected as it is critical for CD4+ T activation [27]. How-
ever, the production in IFN-γ was surprising. Although 
speculative, it is possible that the increase in IFN-γ was 
mediated by PARP-1−/− CD4+ T cells in the presence of 
IL-2 produced by the adoptively transferred WT CD4+ 
T cells. It is also possible that the increase in IFN-γ may 
be mediated by PARP-2. This is based on the observa-
tion that PARP-1 gene knockout only slightly increase 
the expression of the Th1 cytokine while treatment with 
olaparib, which inhibits both PARP-1 and PARP-2, sub-
stantially increased it (Figure  3c). It is important to 
acknowledge that the study, as conducted, does not cover 
all the aspects of asthma manifestation and it remains to 
be determined whether the transfer of WT CD4+ T cells 
is sufficient to reverse AHR and mucus production in 
PARP-1−/− mice. Although more specific experimenta-
tion is required, it is tempting to conclude from the adop-
tive transfer study that PARP-1 may not play a direct role 
in B cell function. The adoptive transfer of OT-II CD4+ T 
cells was sufficient to induce substantial levels of OVA-
specific IgE. Such immunoglobulin production could 
Figure 5 Purified CD4+ T cells procured from spleens of OVA‑sensitized WT or PARP‑1−/− mice were stimulated with anti‑CD3 and anti‑CD28 
antibodies and then skewed into a Th1 or Th2 phenotype in the presence or absence of 5 μΜ olaparib. RNA was extracted then used to generate 
corresponding cDNA followed by quantitative PCR with primer sets specific for mouse gata‑3, il‑4, t‑bet, ifn‑γ, or β‑actin. Data is expressed as fold 
change with β‑actin as a reference gene. Asterisk difference from CD3/CD28‑stimulated cells; p < 0.01.
Page 9 of 12Ghonim et al. J Transl Med  (2015) 13:225 
a b
c
d
Figure 6 a OT‑II mice were sacrificed and CD4+ T cells were skewed towards a Th2 phenotype in presence of the OT‑II peptide. Cells (1 × 106 per 
mouse) were injected i.v. into the tail vein of naïve WT or PARP‑1−/− recipient mice. All mice were subjected to aerosolized OVA challenge daily for 
4 consecutive days. Forty‑eight hours later, mice were sacrificed and subjected to BAL. BALF were subjected to total cell count. Sera were assessed 
for OVA‑specific IgE (b). BALF were also assessed for the Th2 cytokines IL‑4, IL‑5, IL‑10, and GM‑CSF (c) or the Th1 cytokines IL‑2 and INF‑γ (d). Asterisk 
difference from control WT mice, p < 0.01; hash difference from WT mice receiving adoptive transfer (WT (+WT Th2), p < 0.01.
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have only been produced by PARP-1−/− B cells clearly 
suggesting that the function of these cells is comparable 
to that of WT B cells in response to OVA challenge. We 
speculated in our previous studies that the primary rea-
son for the reduced production of IgE upon PARP inhibi-
tion is the effect on IL-4 production [5, 6]. We cannot, 
however, exclude the possibility that PARP plays a role in 
B cell trafficking especially when considering the effect 
of PARP inhibition, pharmacologically or by gene knock-
out, on the overall recruitment of lymphocytes to the 
lung as shown in Figures 1b and 2b. The role of PARP-1 
in GATA-3 expression may be the driving cause for the 
ability of PARP inhibition to reduce IL-4, IL-5, and IL-13 
production. It is noteworthy that GATA-3 is the master 
regulator for the development of Th2 cells [28] through 
its ability to control the activation of the Il4/Il5/Il13 
cytokine locus.
The role of PARP-1 in T-reg cell accumulation has been 
reported in mice, which was associated with an increase 
in Foxp3 [29]. We confirm these results in the experimen-
tal AAI setting. Although olaparib increased the T-reg 
(CD4+/CD25+/Foxp3+) cells upon a single or repeated 
OVA challenge, T-reg cells were increased in PARP-1−/− 
mice regardless of challenge with OVA. This suggests that 
PARP-1 moderately regulates T-reg cells but not upon an 
inflammatory response. Whether the slight increase in 
T-reg cells is a major driving force in the anti-inflamma-
tory effect of PARP inhibition is not clear. Interestingly, a 
recent study demonstrated that T-reg cells isolated from 
PARP-1−/− mice are as functional as those isolated from 
WT mice [30]. Overall, the present studies provide criti-
cal information on the role of PARP-1 upon an acute or 
established AAI and AHR and provide support to the 
notion that PARP can be targeted for the treatment of 
some aspects of human asthma.
Almost two dozen clinical trials most of which are in 
phase II or III are currently examining the possibility of 
establishing olaparib as a mono or adjuvant therapy for 
some specific cancers with BRCA mutation [19]. It is 
noteworthy that there are additional drugs with vary-
ing potency in inhibiting PARP under clinical trials most 
of which focus on the synthetic lethality induced by the 
drugs in BRCA-mutant cancer cells [19]. This phenom-
enon, as stated above, spares normal cells while target-
ing specifically the mutant cancer cells leading to their 
demise as a result of the accumulation of a fatal level of 
dsDNA breaks. It is important to note that the overarch-
ing assumption of these clinical trials is that these drugs 
do not have any important negative effects on normal 
cells and tissues. According to a clinical trial conducted 
by Fong et  al. [21], a total of 200  mg olaparib, daily for 
more than 24 weeks, did not cause any side effects. This 
dose represents a 2.3  mg/kg for men with an average 
weight of 87 and 2.69  mg/kg for women with an aver-
age weight of 74.4. These doses fall between the 1 and 
5 mg/kg doses used in the current study with which we 
observed substantial protection against experimental 
asthma. It is important to note that in the aforemen-
tioned clinical study and others [31–33] on higher doses 
of olaparib for patients with breast or ovarian cancer, the 
most common side effects were nausea, vomiting, fatigue 
and anemia. Despite these effects, discontinuation of the 
drug due to these side effects was a rare event. Addition-
ally, patients with advanced cancer may be more prone 
to adverse events than asthma patients. Nevertheless, 
this would need to be tested closely in any human clini-
cal study. The likely reduced side effects associated with 
the use of low doses of olaparib or other PARP inhibitors 
is very promising for the potential use of these drugs in 
treatment regimens against human asthma. Further-
more, treatment regimens may be extensive and lengthy 
in cancer, which may not be the case in asthma predict-
ing that the use of olaparib in asthma may be associated 
with lesser side effects. Perhaps the therapeutic potential 
of olaparib may become more relevant to difficult to treat 
asthma especially those that do not respond to corticos-
teroids. Although we remain cautious, our study suggests 
that olaparib and potentially other PARP inhibitors are 
ready for testing on human asthma.
Conclusion
Overall, the results of the present study provide more 
support for the role of PARP-1 in asthma pathogenesis 
and the potential of PARP inhibition as a viable therapeu-
tic strategy for the treatment of asthma in humans. More 
importantly, our results propose olaparib as a likely can-
didate to be tested in human asthma clinical trials.
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